Home > Cardiology > ACC 2021 > Heart Failure and Cardiomyopathy > Mavacamten significantly improves QoL of patients with hypertrophic cardiomyopathy

Mavacamten significantly improves QoL of patients with hypertrophic cardiomyopathy

Presented By
Prof. John Spertus, Saint Luke’s Mid America Heart Institute, USA
Conference
ACC 2021
Trial
Phase 3, EXPLORER-HCM
Mavacamten improved the physical and social function and quality of life in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) compared with placebo, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). Prof. John Spertus (Saint Luke’s Mid America Heart Institute, MO, USA) presented a health status analysis of the previously published phase 3 EXPLORER-HCM trial results [1–3]. Current guideline-recommended pharmacological management of HCM mainly consists of β-blockers or calcium channel blockers. Mavacamten is a first-in-class myosin inhibitor that directly addresses the pathophysiological mechanism underlying HCM. The EXPLORER-HCM (NCT03470545) trial was a phase 3 randomised, double-blind, placebo-controlled study that compared mavacamten (n=123) with placebo (n=128...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on